Novo Nordisk A/S

Latest Novo Nordisk A/S News and Updates

  • uploads///Novo RV multiples
    Earnings Report

    Is Novo Nordisk Trading at a Discount or Premium?

    For the last five years, Novo Nordisk (NVO) has been trading at higher multiples when compared with peers.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    Why the Majority of Analysts Deem Novartis a ‘Buy’

    Novartis met Wall Street analysts’ estimates for EPS (earnings per share) in 4Q16, reporting EPS of $1.12 as estimated but missing revenue estimates.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Is Focusing on These Strategic Areas in 2016

    With 642 million people expected to suffer from diabetes globally by 2040, the disease is expected to offer multiple growth opportunities for Novo Nordisk.

    By Margaret Patrick
  • uploads///drug _
    Earnings Report

    Analysts’ Recommendations for Sanofi Stock before Q2 Results

    Sanofi (SNY) is scheduled to announce its earnings results for the second quarter of fiscal 2018 on July 31.

    By Sarah Collins
  • uploads///NOK Oct
    Macroeconomic Analysis

    Norwegian Krone Extended Appreciation Trend Last Week

    The Norwegian krone appreciated against the US dollar on October 9, 2015, as a result of positive inflation data.

    By David Meyer
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Continues to Be a Leader in the Global Insulin Market

    Accounting for a ~46% market share, Novo Nordisk (NVO) is expected to continue to benefit from the positive trends in the global insulin market

    By Margaret Patrick
  • uploads///DKK Nov
    Macroeconomic Analysis

    Danish Krone Fell and Inflation Was below the Forecasts

    The Danish krone fell against the US dollar on November 10, 2015. The inflation figures for October were below the expectations.

    By David Meyer
  • uploads///pill _
    Company & Industry Overviews

    Sanofi Stock: How Much Upside Potential Does Wall Street See?

    In the second quarter of fiscal 2018, Sanofi (SNY) reported sales of 8.2 billion euros, a YoY (year-over-year) decline in sales as well as profits.

    By Sarah Collins
  • uploads///Alliance in companeis based in US Japan
    Company & Industry Overviews

    Multinational and Japanese Pharmaceuticals Should Build Alliances

    The Japanese pharmaceuticals market is not very welcoming to foreign companies. Similarly, the Japanese population is quite loyal to domestic manufacturers.

    By Jillian Dabney
  • uploads///hemophilia drugs
    Company & Industry Overviews

    What Are the Current Treatment Options for Hemophilia?

    Hemophilia treatment primarily includes factor replacement therapy and prolonged half-life therapy such as factor VIII or factor IX infusion.

    By Jillian Dabney
  • uploads///Asset Size and Expense Ratio of Some International MFs
    Macroeconomic Analysis

    Analysis of International Mutual Funds: Investor Takeaways

    For investors interested in international mutual funds, the next step is to evaluate the investment style, as well as risk and return metrics like the Sharpe ratio and standard deviation.

    By David Ashworth
  • uploads///sek
    Macroeconomic Analysis

    Swedish Krona and Danish Krone Depreciate after Inflation Reports

    The Swedish krona depreciated against the US dollar by more than 1% on December 10, 2015, as inflation levels released below estimates for November.

    By David Meyer
  • uploads///Chart  NVO
    Miscellaneous

    Performance of Novo Nordisk Stock in 2Q17

    Novo Nordisk (NVO) stock has risen ~18.6% in 2Q17. It has risen ~16.9% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Analysts’ Recommendations for GlaxoSmithKline in May

    GSK reported EPS of 24.60 British pence on revenue of 7.22 billion pounds, surpassing Wall Street analysts’ consensus estimates.

    By Mike Benson
  • uploads///pill _
    Healthcare

    These Pharma Stocks Offer the Most Upside Potential

    In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.

    By Kenneth Smith
  • uploads///Chart
    Earnings Report

    What Analysts Expect from Pfizer in the Years to Come

    Due to Pfizer’s (PFE) strong Innovative Products business and product pipeline, analysts estimate that it will generate $0.54 in earnings per share in 1Q16.

    By Mike Benson
  • uploads///stock trading monitor desk
    Consumer

    Renaissance Technologies: Analyzing Its Q3 13F

    At the end of the third quarter, Bristol-Myers Squibb, Celgene, Biogen, UnitedHealth, and Walmart (WMT) were Renaissance Technologies’ top five buys.

    By Rabindra Samanta
  • uploads///diabetes _
    Company & Industry Overviews

    How NVO’s Revenues Are Trending in Fiscal 2019

    Novo Nordisk (NVO) has guided for YoY revenue growth of 2% to 5% at a constant exchange rate in fiscal 2019.

    By Margaret Patrick
  • uploads///laboratory _
    Company & Industry Overviews

    What Analysts Recommend for GlaxoSmithKline and Novo Nordisk

    GlaxoSmithKline (GSK) is up by 5.02%, and Novo Nordisk (NVO) is up by 10.51% in 2019 on a YTD basis.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    GW Pharmaceuticals: Recommendations and Market Capitalization

    Wall Street analysts estimate that GWPH stock could increase ~6.7% over the next 12 months.

    By Mike Benson
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Sanofi Stock Up 2.8% in September: What Lies Ahead?

    On September 27, Sanofi’s (SNY) closing price was $44.84, and its market capitalization was $110.7 billion.

    By Sarah Collins
  • uploads///business _
    Miscellaneous

    Novartis to Divest Portions of Sandoz US to Aurobindo

    Novartis (NVS) announced today that it has agreed to sell select portions of its Sandoz US portfolio to Aurobindo Pharma USA.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Novartis’s Sandoz in Q2 2018

    Novartis’s (NVS) Sandoz reported nearly flat revenues at ~$2.46 billion in Q2 2018 compared to $2.45 billion in the second quarter of 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2

    GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products.

    By Mike Benson
  • uploads///Long acting
    Company & Industry Overviews

    Novo Nordisk’s Long-Acting Insulins: A Performance Overview

    Tresiba, Novo Nordisk’s (NVO) long-acting insulin, generated revenues of 3.7 billion Danish kroner in the first half of 2018.

    By Daniel Collins
  • uploads///syringe _
    Company & Industry Overviews

    Novo Nordisk: A Financial Overview after the First Half of 2018

    Novo Nordisk (NVO) had net revenues of 54.3 billion Danish kroner in H1 2018 compared to 57.1 billion Danish kroner in H1 2017.

    By Daniel Collins
  • uploads///dna _
    Earnings Report

    Novartis Reports Growth in Q2 2018 Earnings

    Novartis (NVS) released its Q2 2018 earnings on July 18 and surpassed Wall Street analysts’ estimates for revenues and EPS.

    By Mike Benson
  • uploads///diabetes
    Company & Industry Overviews

    A Look at Novo Nordisk’s Financial Position

    Novo Nordisk (NVO) reported Q1 2018 revenues of 26.9 billion Danish kroner, compared to 28.5 billion Danish kroner in Q1 2017—down ~5% YoY.

    By Daniel Collins
  • uploads///healthcre
    Healthcare

    How the Healthcare Sector’s Dividend Yield Stacks Up

    The healthcare industry has an average dividend yield of 1.9%.

    By Amanda Lawrence
  • uploads///Tresiba
    Company & Industry Overviews

    Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018

    In 4Q17, Novo Nordisk’s (NVO) Tresiba generated revenues of 1.9 billion Danish kroner, which is a ~48% YoY growth in local currencies.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Novartis’s Innovative Medicines Business in 4Q17

    Overall, the innovative medicines business accounted for ~67.8% of Novartis’s total revenues.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How AstraZeneca’s Other Products Portfolio Performed in 4Q17

    AstraZeneca’s (AZN) other products portfolio reported revenues of ~$1.1 billion during 4Q17, a 17% decline in operating revenues.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How AstraZeneca’s Revenues Trended in 4Q17

    AstraZeneca (AZN) reported 2% growth in operating revenues to ~$5.8 billion during 4Q17 as compared to the revenues of ~$5.6 billion during 4Q16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Semaglutide May Prove to Be an Effective Anti-Obesity Therapy

    Novo Nordisk plans to initiate its Phase 3a program, STEP, to study the efficacy of 2.4 mg of semaglutide once per week in obesity indications in 1H18.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Label Expansion May Boost Xultophy’s Sales in 2018

    In November 2017, Novo Nordisk (NVO) submitted an application to European regulatory authorities to update Xultophy’s label.

    By Margaret Patrick
  • uploads///doctor _
    Company & Industry Overviews

    Saxenda May Continue to Lead in the Diabetes Segment in 2018

    In 2017, Novo Nordisk’s (NVO) Saxenda sales reached 2.6 billion Danish kroner, a YoY (year-over-year) rise of 64%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Xultophy May Prove a Strong Growth Driver for NVO in 2018

    Novo Nordisk’s (NVO) Xultophy reported sales close to 729 million Danish kroner in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Has Developed a Portfolio of New-Generation Insulins

    Novo Nordisk has been creating awareness about the risks of hypoglycemia and the benefits of Tresiba among general practitioners and primary care physicians.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Focuses on Creating Buzz about Tresiba’s Benefits

    Novo Nordisk (NVO) is anticipating the FDA’s decision related to the inclusion of hypoglycemia data from its DEVOTE and SWITCH studies by the end of 1Q18.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Tresiba Emerged as a Blockbuster Therapy in 2017

    In 2017, Novo Nordisk’s (NVO) basal insulin therapy, Tresiba, reported revenue of nearly 7.3 billion Danish kroner and attained blockbuster status.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Will NVO Continue to Lead the Global Insulin Market in 2018?

    Novo Nordisk (NVO) has adopted a market-fit strategy, offering insulin products that are suitable for the different demands of patients in different geographies.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Has a Broad Portfolio for Type 2 Diabetes Care

    According to IQVIA, the global insulin market value grew at a compound average growth rate (or CAGR) of 16.8% from November 2012 to November 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Victoza Continues to Lead in the GLP-1 Segment in 2018

    In 3Q17, Novo Nordisk managed to update Victoza’s label in the United States and Europe.

    By Margaret Patrick
  • uploads///woman _
    Company & Industry Overviews

    GLP-1 Drug Class May Continue to Drive Growth for Novo Nordisk

    According to IQVIA, glucagon-like peptide products currently account for only a 12% share of the global diabetes care market by value.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    Sanofi’s Established Prescription Products in 4Q17

    Renagel and Renvela reported revenues of 155.0 million euros in 4Q17, a 28.5% decline in operating revenues compared to 4Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Performance of Sanofi’s Business Segments in 4Q17

    Sanofi Pasteur reported revenues of ~1.4 billion euros in 4Q17 for 8.7% growth in operating revenues compared to its 4Q16 revenues.

    By Mike Benson
  • uploads///ablynx sanofi partnership
    Company & Industry Overviews

    A Look at Ablynx and Sanofi’s Existing Partnership

    On January 29, 2018, Sanofi (SNY) announced that it had agreed to acquire Ablynx (ABLX) for 3.9 billion euros.

    By Sarah Collins
  • uploads///ABLYNX_TRANSACTION_HIGHLIGHTS
    Company & Industry Overviews

    Highlights of Sanofi’s 3.9 Billion Euro Ablynx Acquisition

    On January 29, 2018, Sanofi announced its acquisition of Belgium-based Ablynx for 45 euros per share, amounting to a total of 3.9 billion euros (or $4.8 billion) in cash.

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    Analysts’ Updates after Sanofi’s Bioverativ Announcement

    In this article, we’ll have a look at Wall Street’s recommendations and target prices following Sanofi’s Bioverativ acquisition announcement.

    By Sarah Collins
  • uploads///PROPHYLAXIS
    Company & Industry Overviews

    Sanofi Leads the Hemophilia Space on Bioverativ Acquisition

    According to Sanofi’s (SNY) 2020 roadmap, the company is focused on sustaining a position of leadership in some of its key markets, including the rare diseases space.

    By Sarah Collins
  • uploads///Chart  Ratings
    Earnings Report

    Analysts’ Recommendations for Novartis after Its 4Q17 Earnings

    Novartis (NVS) is expected to report earnings per share of $1.26 in 1Q18 compared to EPS of $1.13 in 1Q17.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Novartis’s 4Q17 Earnings: Sandoz Business

    Sandoz reported a decline of 4.0% in operating revenues, offset by a 4.0% positive impact of foreign exchange.

    By Mike Benson
  • uploads///Ablynx
    Company & Industry Overviews

    How Sanofi Can Benefit from Ablynx Acquisition

    On January 29, 2018, Sanofi entered an agreement with Ablynx where Sanofi will acquire all of the outstanding ordinary shares of Ablynx.

    By Daniel Collins
  • uploads///Chart  Alcon
    Earnings Report

    Reading the Estimates for Novartis’s Alcon in 4Q17

    For 4Q17, Alcon is expected to report growth in revenues, driven by the increased demand for contact lenses and surgical products.

    By Mike Benson
  • uploads///Chart  Inno Medicines
    Earnings Report

    Behind Novartis’s 4Q17 Estimates: Innovative Medicines

    The Innovative Medicines segment is expected to report growth in operating revenues for 4Q17.

    By Mike Benson
  • uploads///Chart  Segment Revenues
    Earnings Report

    Behind Novartis’s 4Q17 Earnings: Why Some Expect Revenue Growth

    Analysts expect Novartis’s revenues to rise ~3.9% to $12.8 billion in 4Q17, driven by growth in operating revenues across all three segments.

    By Mike Benson
  • uploads///Eloctate
    Company & Industry Overviews

    How Is Bioverativ’s Eloctate Positioned Now?

    In 3Q17, Bioverativ’s (BIVV) Eloctate generated revenue of $186.3 million, reflecting a 41% rise on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Hemlibra
    Company & Industry Overviews

    How Is Roche’s Hemlibra Positioned for 2018?

    Roche’s (RHHBY) Hemlibra is used for the prevention and reduction of the frequency of bleeding episodes in individuals with hemophilia A with factor VIII inhibitors.

    By Daniel Collins
  • uploads///Analysts
    Company & Industry Overviews

    Ozempic Could Boost Novo Nordisk’s Revenue Growth in 2018

    In December 2017, the U.S. FDA (Food and Drug Administration) approved Novo Nordisk’s (NVO) Ozempic as an addition to diet and exercise for the improvement of blood sugar levels in individuals with type two diabetes mellitus.

    By Daniel Collins
  • uploads///Human insulin
    Company & Industry Overviews

    How Did Novo Nordisk’s NovoMix and Human Insulin Perform in 2017?

    In 3Q17, Novo Nordisk’s (NVO) NovoMix reported revenues of 2.4 billion Danish krone (or DKK), which reflected ~1% growth on year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///hemophilia
    Company & Industry Overviews

    How Novo Nordisk’s Biopharmaceuticals Segment Performed in 3Q17

    In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.

    By Daniel Collins
  • uploads///Victoza
    Company & Industry Overviews

    How Did Novo Nordisk’s Victoza and Saxendra Perform in 3Q17?

    In 3Q17, Novo Nordisk’s (NVO) Victoza reported revenues of 5.3 billion Danish krone (or DKK), which reflected ~9% growth on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Modern Insulin
    Company & Industry Overviews

    How Did Novo Nordisk’s Modern Insulin Segment Perform in 3Q17?

    In 3Q17, Novo Nordisk’s (NVO) NovoRapid reported revenues of 5.0 billion Danish krone (or DKK), which reflected ~9% growth on year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///new generation insulin
    Company & Industry Overviews

    Novo Nordisk’s Xultophy, Ryzodeg, and Fiasp Could Boost Revenue Growth in 2018

    Novo Nordisk’s (NVO) Xultophy (insulin degludec and liraglutide combination) is used as an addition to diet and exercise for improvement of blood sugar levels in adults with type-2 diabetes mellitus whose blood sugar level could not be controlled adequately with basal insulin.

    By Daniel Collins
  • uploads///NGI
    Company & Industry Overviews

    How Is Novo Nordisk’s New Generation Insulin Segment Positioned after 3Q17?

    In 3Q17, Novo Nordisk’s (NVO) new generation insulin generated revenues of 2.1 billion Danish krone (or DKK), which reflected ~93% growth on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Behind Sanofi’s Generics and Consumer Healthcare Business in 3Q17

    Sanofi’s (SNY) general medicines and emerging markets sub-segment reported revenues of 433 million euros in 3Q17, representing a 0.9% YoY fall.

    By Mike Benson
  • uploads///Trajenta
    Company & Industry Overviews

    How Eli Lilly’s Trajenta, Trulicity, and Basaglar Are Performing

    In 3Q17, Eli Lilly’s (LLY) Trajenta generated revenues of $153.3 million, ~33% growth on a year-over-year (or YoY) basis and ~8% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Humalog
    Company & Industry Overviews

    How Eli Lilly’s Endocrinology Drugs Are Performing

    In 3Q17, Eli Lilly’s (LLY) Humalog generated revenues of $696.2 million, ~9% growth on year-over-year (or YoY) basis and 3% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Forteo
    Company & Industry Overviews

    How Eli Lilly’s Forteo and Jardiance Are Performing

    In 3Q17, Eli Lilly’s (LLY) Forteo generated revenues of $441.7 million, ~13% growth on a year-over-year (or YoY) basis and a 1% decline on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Chart  Ratings
    Company & Industry Overviews

    Analysts’ Recommendations for GlaxoSmithKline in November 2017

    Wall Street analysts estimate that GlaxoSmithKline’s (GSK) top line could fall 0.8% to ~7.5 billion pounds in 4Q17.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Behind Sanofi’s 3Q17 Revenue Growth

    Sanofi (SNY) reported a growth of 4.7% in revenues at constant exchange rates to 9.05 billion euros, compared with 9.03 billion euros in 3Q16.

    By Mike Benson
  • uploads///Chart  NVO
    Miscellaneous

    Novo Nordisk Stock: Performance in 3Q17

    Novo Nordisk stock has risen ~12.3% in 3Q17. It has risen ~41.3% year-to-date as of October 20, 2017.

    By Mike Benson
  • uploads///Chart  GSK
    Miscellaneous

    What GlaxoSmithKline’s 3Q17 Performance Tells Us

    GSK stock fell ~4.7% in 3Q17 but has risen ~6.0% YTD (year-to-date) as of October 16.

    By Mike Benson
  • uploads///Basaglar
    Company & Industry Overviews

    Why Eli Lilly’s Basaglar, Jardiance, and Trajenta Could Witness Steady Growth in 2018

    In 1H17, Eli Lilly’s (LLY) Basaglar generated revenues of around $132.6 million, compared with $27.2 million in 1H16.

    By Daniel Collins
  • uploads///Chart  MRK
    Healthcare

    Behind Merck’s Performance in 3Q17

    MRK stock rose ~0.6% in 3Q17 and has risen ~7.7% YTD (year-to-date) as of October 16.

    By Mike Benson
  • uploads///Victoza revenues
    Company & Industry Overviews

    How Is Novo Nordisk’s Victoza Positioned after 2Q17?

    In the first half of 2017, Novo Nordisk’s (NVO) Victoza generated revenues of DKK (Danish kroner) 11.5 billion, which reflected a ~21.0% rise on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Xultophy
    Company & Industry Overviews

    Xultophy Could Substantially Boost Novo Nordisk’s Revenue Growth

    In the first half of 2017, Novo Nordisk’s (NVO) Xultophy generated revenues of DKK (Danish kroner) 284.0 million.

    By Daniel Collins
  • uploads///BioMarins Developmental
    Company & Industry Overviews

    BioMarin’s Strong Pipeline Could Be a Long-Term Growth Driver

    After success in the company’s phase 1/2 trial with BMN 270, an investigational gene therapy for hemophilia A, BioMarin Pharmaceuticals (BMRN) is expected to start phase 3 trials.

    By Daniel Collins
  • uploads///Chart  Gardasil
    Company & Industry Overviews

    How Merck’s Gardasil and Other Human Vaccines Performed in 2Q17

    Merck’s (MRK) Gardasil franchise includes vaccines for the prevention of certain strains of HPV infections that are sexually transmitted.

    By Mike Benson
  • uploads///Clinical trial
    Company & Industry Overviews

    This Part of Bioverativ’s Pipeline Could Be a Major Long-Term Growth Driver

    In June 2017, the FDA accepted Bioverativ’s investigative new drug application for BIVV001, a drug designed to treat prophylaxis from bleeding associated with hemophilia A.

    By Daniel Collins
  • uploads///Alprolix Eloctate
    Company & Industry Overviews

    How Are Bioverativ’s Key Drugs Positioned after 2Q17?

    In 2Q17, Bioverativ’s Alprolix generated revenues of ~$89.7 million, which represents ~12% growth YoY (year-over-year) and ~4% growth sequentially.

    By Daniel Collins
  • uploads///Chart  Rev
    Company & Industry Overviews

    Chart in Focus: AstraZeneca’s Revenues in 2Q17

    AstraZeneca (AZN) reported a decrease of ~10% in its top line at ~$5.1 billion for 2Q17, compared to revenues of $5.6 billion for 2Q16.

    By Mike Benson
  • uploads///Chart  Con
    Company & Industry Overviews

    GlaxoSmithKline’s Consumer Healthcare Business Improved

    GlaxoSmithKline (GSK) added new products and improved the supply chain for consumer healthcare products in the last few years.

    By Mike Benson
  • uploads///Chart  SWR
    Company & Industry Overviews

    How Did GlaxoSmithKline’s Segments Perform in 2Q17?

    GlaxoSmithKline’s Pharmaceuticals segment reported revenues of 4.36 billion pounds during 2Q17—12% growth compared to 2Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Johnson & Johnson’s Medical Devices Segment in 2Q17

    Medical devices segment Johnson & Johnson’s (JNJ) medical devices segment reported revenue of $6.7 billion in 2Q17, a growth of 4.9% from the revenue of $6.4 billion reported in 2Q16. This figure included 5.9% growth in operating revenue, and was partially offset by a 1% foreign exchange impact. Cardiovascular care franchise The cardiovascular care franchise […]

    By Mike Benson
  • uploads///Chart  GCHC
    Company & Industry Overviews

    Sanofi’s General Medicines and Consumer Healthcare in 2Q17

    General Medicines Sanofi’s (SNY) generic business contributed ~5.1% of its total revenue in 2Q17. The business reported revenue of 442 million euros in 2Q17, an 8% decrease from 2Q16. Revenue fell due to lower sales in US markets, European markets, and emerging markets. This fall was partially offset by the growth in the rest of […]

    By Mike Benson
  • uploads///Chart  ERx
    Company & Industry Overviews

    Performance of Sanofi’s Established Products in 2Q17

    Established products Sanofi’s (SNY) established products contributed over 29.5% of its total revenue in 2Q17. Established product revenue, which fell 2.3% at constant exchange rates in 2Q17, stood at 2.6 billion euros. Lower sales of Plavix, Lovenox, Allegra, Myslee, Lasix, and a few other drugs were substantially offset by strong performance by Renagel, Renvela, Aprovel, Synvisc, […]

    By Mike Benson
  • uploads///Chart  Genzyme
    Company & Industry Overviews

    Sanofi Genzyme Continues Driving Revenue Growth in 2Q17

    Sanofi Genzyme In 2Q17, Sanofi Genzyme (SNY) reported revenue growth of 13.5% to 1.7 billion euros. Considering a constant structure and constant exchange rates, the growth was 14.4%. Sanofi Genzyme, which includes product revenue from the multiple sclerosis, rare disease, oncology, and immunology franchises, reported a sales increase of ~14.6% to 1.7 billion euros. This rise was […]

    By Mike Benson
  • uploads///Chart  SWR
    Company & Industry Overviews

    Sanofi’s Revenue Growth in 2Q17

    Sanofi’s revenue in 2Q17 At constant exchange rates, Sanofi (SNY) reported revenue growth of ~5.5% between 2Q16 and 2Q17, with revenue rising to 8.7 billion euros from 8.1 billion euros. Structure of the group The above chart shows Sanofi’s segment-wise revenue over the last few quarters. In 2016, Sanofi reorganized itself into five business units: Sanofi […]

    By Mike Benson
  • uploads///Chart  ProductDev
    Company & Industry Overviews

    Pfizer’s Important Product Developments in 2Q17

    Pfizer’s (PFE) innovative health business and essential health business are focusing on growth. To strengthen the innovative health business, the company is focusing on the development of new drugs…

    By Mike Benson
  • uploads///Chart  EPS
    Earnings Report

    GlaxoSmithKline’s Valuations after Its 2Q17 Earnings

    On July 28, 2017, GlaxoSmithKline (GSK) traded at a forward PE multiple of 13.4x, which is slightly lower than the industry average of 15.2x.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Bioverativ’s Research Pipeline May Boost Future Revenues

    Bioverativ (BIVV) plans to improve compliance rates for hemophilia patients further by launching therapies with lower dosage frequency.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bioverativ’s Eloctate Sees More Demand from Hemophilia A Patients

    In 1Q17, Bioverativ’s Eloctate witnessed revenues close to $155.9 million, which is about $48.0 million more YoY (year-over-year).

    By Margaret Patrick
  • uploads///Chart  Ratings
    Earnings Report

    Analysts’ Recommendations for AstraZeneca in 2Q17

    Wall Street analysts expect AstraZeneca’s top line to fall ~9.5% to $5.1 billion in 2Q17, compared to $5.6 billion in 2Q16. Its earnings per share are expected to be $0.42 in 2Q17.

    By Mike Benson
  • uploads///Chart  Sandoz
    Earnings Report

    Novartis in 2Q17: Performance of Sandoz

    Sandoz contributed ~20.0% of total revenues at $2.45 billion in 2Q17, a 5.0% fall compared to $2.58 billion in 2Q16.

    By Mike Benson
  • uploads///Chart  Segment
    Earnings Report

    Foreign Exchange Impacts Novartis’s Growth in 2Q17

    In its earnings release on July 8, 2017, Novartis (NVS) reported flat revenues at constant currencies for 2Q17.

    By Mike Benson
  • uploads///Chart  Con
    Earnings Report

    Johnson & Johnson: Consumer Products in 2Q17

    The consumer segment Johnson & Johnson’s (JNJ) consumer segment revenue rose 1.7% to $3.5 billion in 2Q17, compared with $3.4 billion in 2Q16. This rise includes operational growth of 2.3%, which was offset by a 0.6% impact of foreign exchange. Baby care franchise The baby care franchise reported revenue of $494 million in 2Q17, a […]

    By Mike Benson
  • uploads///Chart  Inno Medicines
    Earnings Report

    Novartis’s 2Q17 Estimates: Innovative Medicines Segment

    The overall contribution of Novartis’s (NVS) Innovative Medicines segment is ~67.0% of its total revenues.

    By Mike Benson
  • uploads///Chart  Rev n EPS
    Earnings Report

    Analysts Expect Novartis’s Revenues to Fall in 2Q17

    Analysts expect Novartis’s (NVS) revenues to fall ~1.6% to $12.3 billion in 2Q17 due to the effects of the acquisition and divestiture of some of its products.

    By Mike Benson
  • uploads///Chart  AR
    Earnings Report

    Analysts’ Latest Recommendations for Johnson & Johnson

    Johnson & Johnson (JNJ) missed Wall Street analysts’ revenue estimates in 1Q17. It reported revenue of $17.8 billion in the quarter.

    By Mike Benson
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.